Biotherapeutics and Antibody Modeling

Biotherapeutics offer a range of unique benefits over small molecule drugs. Their increased affinity and selectivity have allowed researchers to address new and difficult targets. This has led to a dramatic increase in R&D projects centered on antibodies and other biological modalities for treatment such as bispecifics. However, these projects must also overcome similar challenges in safety and pharmacokinetics faced by small molecules, albeit from a different perspective. Factors such as high immunogenicity or low solubility can kill development on an otherwise effective candidate.

Modeling and simulation can significantly advance the development of these new classes of therapeutics. For example, researchers can predict an antibody’s formulation properties and suggest mutations to improve them rapidly and at low cost compared to laboratory experimentation alone. BIOVIA Discovery Studio offers a rich set of tools to help guide the design of biotherapeutics, allowing teams to optimize the performance of candidates in silico and streamlining their physical work.